Insights

Paul Feuerstadt, MD, FACG, AGAF, discusses how antibiotics remain the initial treatment for Clostridioides difficile infections, but due to limited efficiency and recurrence rates, newer therapies including fecal microbiota transplantation (FMT), Rebyota (a purified live biotherapeutic), and Vowst (an oral microbiota therapeutic) have emerged as FDA-approved options that restore gut microbiome diversity and show promising efficiency in preventing recurrent infections, particularly in patients who have failed standard antibiotic therapy.

Reynold A. Panettieri Jr., MD, discusses the role of type 2 inflammation in COPD and asthma, emphasizing its potential to impair lung function.

Justin Oldham, MD, MS, provides clinical insights on the evolving treatment landscape in idiopathic pulmonary fibrosis.

Iltefat Hamzavi, MD, provides comprehensive insights on hidradenitis suppurativa (HS), highlighting disease characteristics, treatment practices, and the disease’s profound impact on patients and families.

Ronald Oudiz, MD, FACP, FACC, FCCP, provides clinical insights on the evolving treatment landscape for patients with pulmonary arterial hypertension, focusing onemerging therapies and integrating them into clinical practice.

Robert Gabbay, MD, PhD, discusses type 1 diabetes by addressing the distinct stages of the disease, risk factors, and current and emerging treatments.

Elizabeth Spencer, MD, discusses treatments for eosinophilic esophagitis (EoE), caregiver challenges, therapy struggles, insurance hurdles, and patient advocacy needs.

Expert perspective delves into nature of bronchiectasis and navigates its current treatment landscape across various patient populations.

Mirna Chehade, MD, MPH, describes the symptoms of eosinophilic esophagitis in pediatric patients, and discusses the importance of prompt diagnosis, tailored treatments, and shared decision-making for better patient outcomes.

Elizabeth Yeu, MD, highlights the current landscape of Demodex blepharitis and available treatment options.

Joseph M. Coney MD, FACS, discusses key factors needed to address disparities in care among patients with diabetic macular edema, including the significance of community involvement and the role of provider self-reflection in facilitating fair and unbiased medical care.

Experts discuss novel therapies, unmet needs, and supportive care measures for patients with metastatic non-small cell lung cancer (mNSCLC).

A medical expert discusses current and prospective treatment strategies for RSV.

Eliot Brinton, MD, highlights disease burden and treatment considerations for patients with homozygous familial hypercholesterolemia (HoFH).

David Lieberman, MD, PhD, provides an overview of Rett Syndrome, explores the patient perspective of Rett Syndrome, and discusses methods clinicians and payers use to evaluate treatment successes.

Two experts discuss the burden of disease, the treatment landscape, and the urgency to treat lupus nephritis.

A panel of experts discuss the treatment landscape of upper GI cancer, as well as unmet needs in GI, gastric, gastroesophageal junction, and esophageal cancers.

Three experts discuss HIV management with PrEP therapies, highlighting the major obstacles that can impact these patients and what can be done to improve their quality of life.

Three experts discuss the use of biosimilar and interchangeable biosimilars, exploring how the treatment landscape will change in the upcoming years.

A panel of expert medical professionals navigate the evolving landscape in biomarker testing for treating patients with metastatic colorectal cancer.

Three experts discuss advanced non-small cell lung cancer and what it means to have a treat a KRAS G12C mutation.

Two experts, one provider and one payer, shed light on their experiences with prescription digital therapeutics within the behavioral care landscape.

Two experts discuss the role immunomodulatory drugs (IMiDs) play in the current treatment landscape for relapsed/refractory multiple myeloma and how they can be used effectively.

Ian Riddock, MD, and Eliot Brinton, MD, discuss effective use of lipid lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD).

Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.